Details
Stereochemistry | RACEMIC |
Molecular Formula | C37H42N4O2.2Cl.Sn |
Molecular Weight | 764.371 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | -4 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[SnH4].CCOC(=O)C1=CC2=C3[N-]C(=CC4=NC(=CC5=C(CC)C(C)=C([N-]5)C=C6N=C2C(C)=C6CC)C(C)=C4CC)[C@@H](C)[C@]13CC
InChI
InChIKey=DILGWZXJUXYRHF-QNVJIRAVSA-K
InChI=1S/C37H43N4O2.2ClH.Sn.2H/c1-10-23-19(6)29-17-33-25(12-3)21(8)34(40-33)26-15-27(36(42)43-14-5)37(13-4)22(9)30(41-35(26)37)18-32-24(11-2)20(7)28(39-32)16-31(23)38-29;;;;;/h15-18,22H,10-14H2,1-9H3,(H-,38,39,40,41,42);2*1H;;;/q-1;;;;;/p-3/t22-,37-;;;;;/m1...../s1
Molecular Formula | Cl |
Molecular Weight | 35.453 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Sn |
Molecular Weight | 118.71 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C37H42N4O2 |
Molecular Weight | 574.755 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Rostaporfin (SnET2, Purlytin, REM-001), a second generation photosensitizer drug, that was developed as part of Miravant's PhotoPoint photodynamic therapy (PDT) program, for the potential treatment of wet age-related macular degeneration (AMD). It was found a red light with a wavelength of 664 nm activated the drug. It is injected into the patient, where it distributed and selectively bound to plasma lipoproteins, which were produced in high concentrations by hyperproliferating cells such as cancer cells. In January 2002, results of phase III trials indicated that rostaporfin had not met the primary efficacy endpoint for the wet form of AMD. In addition, rostaporfin has been studied in phase 2 and/or Phase 3 clinical trials in cutaneous metastatic breast cancer (CMBC). It was shown that the drug was able to reduce or eliminate a substantial number of treated CMBC tumors. On March 1, 2018, Adgero Biopharmaceuticals Holdings, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to REM-001 (rostaporfin), for the treatment of Basal Cell Carcinoma Nevus Syndrome (“BCCNS”). BCCNS is a rare but serious condition with few available therapies and many patients lack treatment options.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9853137
Each patient underwent a single photodynamic therapy session in which 1.2 mg/kg of the drug tin ethyl etiopurpurin (Purlytin) was injected and followed 24 hours later by laser light treatment at 660 +/- 3 nm (at 150 mW/cm2 for a total light dose of 200 J/cm2).
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:39:51 GMT 2023
by
admin
on
Fri Dec 15 15:39:51 GMT 2023
|
Record UNII |
466G63QE7G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
168703
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
||
|
FDA ORPHAN DRUG |
620517
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
||
|
NCI_THESAURUS |
C1420
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C171132
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY | |||
|
300000034364
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY | |||
|
7966
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY | |||
|
466G63QE7G
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY | |||
|
284041-10-7
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY | |||
|
m9671
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB06659
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY | |||
|
C063166
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY | |||
|
KK-52
Created by
admin on Fri Dec 15 15:39:51 GMT 2023 , Edited by admin on Fri Dec 15 15:39:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |